After a difficult year seeing global revenue for drug eluting stents declining to US3.9 billion globally from a peak of US$5.1 billion in 2005, the market for drug-coated stents is getting back on track.
Over publicized negative outcome results from a sub-group of clinical studies triggered a reduction in total percutaneous coronary intervention procedures as well as a decrease in penetration levels of drug eluting stents share of these procedures.
New studies emerging from European Society of Cardiology (ESC) and the Transcatheter Cardiovascular Therapeutics (TCT) conferences have re-asserted the underlying safety and efficacy of DES, and challenged earlier negative late stent thrombosis results.
As the dust settles, early positive trends in drug coated stents global sales are emerging and impressive new product launches are expected in the US market in 2008. Waning COURAGE impact combined with favorable media response to newer longer-term trial results are leading to better device prescription volumes in all geographical segments.
It provides a timely analysis of this market with profiles of leading participants and forecasts to the year 2015.
With Drug Eluting Stents - Technology & Market Forecast, you’ll be able to:
1. Understand current market dynamics, competitors positions and market shares.
2. Assess market size and growth potential for these combined drug devices.
3. Monitor the competition’s marketed and in-development products.
4. Identify emerging technologies and the companies behind them.
5. Assess market potential and have access to forecasts till 2015.
6. Leverage your own technology and brain storm new business opportunities.
7. Investigate mergers, acquisitions and licensing possibilities
Drug Eluting Stents - Technology & Market Forecast is targeted at busy senior executives in medical technology companies who are interested in developing an understanding of this highly dynamic evolving market.
